支气管肺泡灌洗液mNGS与传统微生物检测对重症肺炎病原鉴定及预后临床价值:前瞻性多中心随机临床试验方案(NT-BALF)
本研究为前瞻性多中心开放随机对照试验,计划纳入中国4家大型三级医院的192例重症肺炎患者,比较支气管肺泡灌洗液mNGS联合传统微生物检测与单用传统检测对28天全因死亡率的影响,并评估ICU及住院时长、无 ventilator 天数、检测一致性、检出率、周转时间、抗菌方案及ICU费用等次要结局。
要点
- 计划纳入192例重症肺炎患者,随机1:1分为mNGS联合传统检测组与传统检测组。
- 主要结局为28天全因死亡率,次要结局包括ICU及住院时长、无创通气天数等。
- 所有患者均采集支气管肺泡灌洗液,根据分析结果选择个体化抗菌治疗方案。
核心结论
- mNGS的临床获益可能显著,但其局限性也应予以考虑。
研究设计与样本
- 区域多中心、开放、前瞻性随机对照试验,计划从中国4家大型三级医院招募192例重症肺炎患者。
- 所有患者获取支气管肺泡灌洗液,按1:1随机分配至研究组(mNGS联合传统微生物检测)或对照组(仅传统微生物检测)。
主要发现
- 该研究旨在评估mNGS联合传统检测能否以中等成本效果降低28天全因死亡率。
- 次要结局包括ICU及住院时长、无 ventilator 天数及无ICU天数、mNGS与传统检测的一致性、mNGS与传统检测的检出率、周转时间、从分组到开始治疗的时间、血管升压药支持时长、抗感染方案类型与时长、耐药细菌或真菌来源及ICU费用。
关键数值与推荐
- 主要结局为28天全因死亡率。
- 计划样本量为192例重症肺炎患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early, rapid, and accurate pathogen diagnosis can help clinicians select targeted treatment options, thus improving prognosis and reducing mortality rates of severe pneumonia. Metagenomic next-generation sequencing (mNGS) has a higher sensitivity and broader pathogen spectrum than traditional microbiological tests. However, the effects of mNGS-based antimicrobial treatment procedures on clinical outcomes and cost-effectiveness in patients with severe pneumonia have not been evaluated. METHODS: This is a regional, multi-center, open, prospective, randomized controlled trial to evaluate that whether the combination of mNGS and traditional testing methods could decrease 28-day call-cause mortality with moderate cost-effectiveness. A total of 192 patients with severe pneumonia will be recruited from four large tertiary hospitals in China. Bronchoalveolar lavage fluid will be obtained in all patients and randomly assigned to the study group (mNGS combined with traditional microbiological tests) or the control group (traditional microbiological tests only) in a 1:1 ratio. Individualized antimicrobial treatment and strategy will be selected according to the analysis results. The primary outcome is 28-day all-cause mortality. The secondary outcomes are ICU and hospital length of stay (LOS), ventilator-free days and ICU-free days, consistency between mNGS and traditional microbiological tests, detective rate of mNGS and traditional microbiological tests, turn-out time, time from group allocation to start of treatment, duration of vasopressor support, types and duration of anti-infective regimens, source of drug-resistant bacteria or fungi, and ICU cost. DISCUSSION: The clinical benefits of mNGS are potentially significant, but its limitations should also be considered. TRIAL REGISTRATION: ChineseClinicalTrialRegistry.org, ChiCTR2300076853. Registered on 22 October 2023.
引用
- Song X, Jiang H, Zong L, et al. The clinical value of mNGS of bronchoalveolar lavage fluid versus traditional microbiological tests for pathogen identification and prognosis of severe pneumonia (NT-BALF):study protocol for a prospective multi-center randomized clinical trial. Trials. 2024. PMID: 38650051. doi:10.1186/s13063-024-08112-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。